MS
ITCI

Maven Securities’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Maven Securities’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-520,700
Closed -$68.7M – 1006
2025
Q1 		$68.7M Buy
+520,700
New +$64.9M 2.1% 7

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Maven Securities's ITCI Position: Q2 2025 in Review

Maven Securities sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 29,000 shares — an estimated $3.83M sold.

Maven Securities first reported a position in ITCI in Q4 2020 and held it in 4 quarters. The position peaked at $3.83M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Maven Securities reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Maven Securities sold 29,000 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $3.83M.
  • Maven Securities first reported a position in Intra-Cellular Therapies Inc. in Q4 2020 and held it in 4 quarters.
  • Maven Securities's Intra-Cellular Therapies Inc. position peaked at $3.83M in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Maven Securities's 13F filing for Q2 2025, filed 14 Aug 2025.